secwatch.observer — SEC 8-K summary
======================================

Issuer:     Omega Therapeutics, Inc. (—)
CIK:        0001850838
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0000950170-24-038053
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omega Therapeutics reports FY 2023 net loss $97.4M; cuts headcount 35%, extends cash runway to Q1 2025
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $73.4M as of Dec. 31, 2023; expected to fund operations into Q1 2025.
- OTX-2002 in HCC showed 80% disease control rate (4/5) in early cohorts; Cohort 5 (0.3 mg/kg) opened in March 2024.
- Novo Nordisk collaboration for obesity: up to $532M in milestones plus tiered royalties; target enhances thermogenesis.
- R&D expense $77.2M in 2023 vs $81.2M in 2022; net loss $97.4M vs $102.7M; headcount reduced ~35%.
- Prioritized programs: OTX-2101 (NSCLC), HNF4A (liver regeneration), obesity controller; expect next clinical data mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850838/000095017024038053/0000950170-24-038053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850838/000095017024038053/omga-20240328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-038053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer